Inside a 1,000 L high-shear dissolving line serving swine and poultry drinking-water concentrates, Zhuling Powder (Polyporus umbellatus sclerotium powder) is dry-blended with 1–2 wt% fumed silica in a 600 L double-cone blender at 6 rpm for 20 min before transfer into a 500 L LDPE tote containing purified water heated to 38–42°C. The silica pre-blend is not a dosage-form filler; it conditions the surface charge of the API and prevents the electrostatic clumping observed when raw Zhuling Powder is discharged directly from 25 kg fibre drums into the liquid phase. Under warehouse conditions where relative humidity exceeds 60%, the incoming powder is tray-dried at 45°C for 6–8 h until loss-on-drying falls below 5.0%; otherwise, the double-cone blender charge cakes within 10–15 min and content uniformity of the finished concentrate misses the ±5% in-process target. The liquid concentrate is prepared at 10–30 wt% total solids, equivalent to 100–300 g/L of the API powder, and the final medicated drinking-water dilution is set only by the veterinarian or the marketing-authorization holder according to species-specific dosing. In-line processing includes recirculation through a 200 μm basket strainer and a 0.45 μm polyethersulfone membrane cartridge for 25–35 min, with turbidity controlled by a 90° nephelometer at below 10 NTU. Because published pharmacopoeial solubility data for this particular veterinary API configuration are limited, each production lot is subjected to a hydration study in the intended water matrix at 25°C and 5°C to confirm that the D90 particle size remains below 80 μm after 60 min of recirculation. Compliance for the finished soluble powder or liquid concentrate is anchored to the Chinese Pharmacopoeia 2020 raw-material identification for Polyporus, VICH GL1 for analytical method validation, VICH GL18 for residual solvents, 21 CFR Part 210/211 for finished-dosage cGMP, and EU Regulation 2019/6 where the product is registered as a veterinary medicinal product in the European Economic Area. The terminal product is either filled into 1 L or 5 L HDPE jugs as a liquid concentrate, or spray-dried onto a maltodextrin–silicon dioxide carrier and packed as a reconstitutable soluble powder in 100 g and 500 g sachets. A documented incompatibility exists with high-valence metal salts such as ferric or aluminium chloride; if such electrolytes are present in the water matrix, polysaccharide flocculation can occur within 30 min, and the final product should be reconstituted only with softened or demineralized water.

What Limits Terminal Sterilization of Polysaccharide-Rich Injection APIs?

Compliance for a sterile Zhuling Powder solution is defined by USP <1>, USP <85> Bacterial Endotoxins Test, USP <788> Particulate Matter in Injections, VICH GL3 stability testing for new veterinary drug substances and medicinal products, and 21 CFR Part 210/211 aseptic-processing requirements. In the compounding area, the API is dissolved in WFI cooled to 15–20°C at a loading of 5–20 mg/mL; the reduced temperature lowers solution viscosity and helps retain the high-molecular-weight polysaccharide fraction during membrane filtration. Sodium chloride at 0.9% w/v is used as the tonicity adjuster, and 0.1–0.3 wt% sodium citrate buffer holds the pH between 5.5 and 7.0; where lyophilized vials are required, 2–4 wt% mannitol or glycine is included as a cryoprotectant and cake former. The bulk solution is clarified through a 0.45 μm PVDF capsule and sterile-filtered through a 0.22 μm PVDF cartridge at 1.5–2.5 bar differential pressure; production-scale records show that sterile filter capacity can decline from 50 L/m² to 15 L/m² if the crude polysaccharide solution is not pre-centrifuged at 8,000 ×g for 20 min before the first filtration step. Terminal autoclaving at 121°C for 15 min is not recommended as a default cycle, because polysaccharide backbone hydrolysis and Maillard browning are possible above 121°C or above pH 7.5 in the presence of reducing sugars or citrate buffers. Aseptic filling is performed in an ISO 14644-1 Class 5 environment with Grade A laminar-airflow protection, and the finished solution is filled into 10 mL, 20 mL, and 50 mL borosilicate Type I glass vials with chlorobutyl rubber stoppers; the lyophilized presentation is filled into 10 mL vials as a freeze-dried cake for reconstitution with WFI immediately before injection. Because published forced-degradation data for this specific Zhuling Powder injection configuration are limited, the terminal-sterilization decision should be supported by supplier-specific pH, temperature, and time studies rather than by analogy to small-molecule APIs.

Capsule Filling Under Low-Humidity Dry-Transfer Conditions

For a production-size 400 mg capsule fill, the dry blend commonly contains 20–50 wt% Zhuling Powder, 45–75 wt% microcrystalline cellulose or lactose monohydrate filler, 2–5 wt% croscarmellose sodium as disintegrant, 0.5–1.0 wt% colloidal silicon dioxide as glidant, and 0.25–1.0 wt% magnesium stearate as lubricant. The API is pre-dried in a forced-convection oven at 45°C until Karl Fischer moisture is below 5.0%, then passed through a 40 mesh stainless-steel sieve before charging a 1,000 L V-blender; dry mixing proceeds at 12 rpm for 15 min, and the lubricant is added for a final 3 min to prevent over-lubrication that would delay capsule dissolution. Encapsulation is run on a dosator-type machine at 40,000–60,000 capsules/h in a room maintained at 20–25°C and 35–45% RH; when RH exceeds 45%, the powder bed becomes tacky, weight variation moves outside the ±5% in-process limit, and powder transfer from the hopper to the dosing disc becomes erratic. The primary compliance references are USP <711> dissolution, USP <921> Karl Fischer water determination, USP <1174> powder flow, and 21 CFR Part 211 for finished pharmaceutical manufacturing; where the capsule is destined for the European Economic Area, VICH GL4 stability data on the marketed capsule formulation supply the storage specification. The terminal finished product is filled into size 0 or size 1 hard gelatin or HPMC capsules, packaged in HDPE bottles with silica gel desiccant, and labelled as a veterinary active-ingredient product for prescription use. A documented boundary condition is the API hygroscopicity above 60% RH; if pre-drying is omitted, batch-to-batch variation in capsule disintegration and dissolution profile is observed on the production line within 24 h of exposure to humid air.

When a 120 kg granulator bowl charge is processed at 32–38°C product temperature in a top-spray fluidized bed, the binder solution is prepared by dissolving PVP K30 at 2–5 wt% of the total dry mass in purified water heated to 55–60°C. The dry charge contains 15–30 wt% Zhuling Powder, 65–80 wt% lactose monohydrate or corn starch, and 0.3–0.8 wt% colloidal silicon dioxide to improve bed fluidization. The spray rate is held at 80–120 g/min per 100 kg batch, with inlet air temperature 55–65°C and atomizing air pressure 1.2–1.8 bar; the endpoint is reached when residual moisture by loss-on-drying is 2.0–4.0% and the product temperature has not exceeded 38°C. Higher product temperatures initiate adhesive particle agglomeration and defluidization within 15–20 min, particularly when the incoming API moisture exceeds 7%. The granulator bowl is discharged through a 10 mesh screen and a 60 mesh screen to isolate the 12–60 mesh fraction; undersize and oversize material is dry-milled or re-granulated only when the rework amount does not exceed 10 wt% of the batch. Compliance for the resulting oral granule includes USP <786> analytical sieving for particle-size distribution, VICH GL3 for stability, and 21 CFR Part 210/211 for batch documentation; if the granule is sold as a bulk intermediate for repacking, the buyer's certificate of analysis should include tapped bulk density by USP <616> and water activity below 0.55 to ensure sachet-line flow. The terminal product is filled into 5 g, 10 g, and 25 g aluminium-LDPE sachets, intended for direct administration or reconstitution in drinking water according to the authorised veterinary prescription.

If Post-Pellet Conditioning Exceeds 80°C in Medicated Premix Lines

Feed-mill premix operations require Zhuling Powder to be incorporated at 2–10 kg per metric ton of complete feed, with the exact rate determined by the veterinary directive and the target animal species. In concentrated premixes, the powder is standardized at 10–25 wt% on a calcium carbonate or rice husk carrier. A 2,000 kg horizontal ribbon mixer is used with a 15 min dry-mix cycle at 20 rpm, followed by a 3–5 min liquid spray of soybean oil at 0.5–1.0 wt% to suppress dust and improve adhesion to the carrier. The finished premix is transferred by gravity into 25 kg paper-PE bags and sealed to maintain moisture below 8%. If post-pellet conditioning exceeds 80°C, the polysaccharide fraction may undergo browning and lose water solubility; therefore, the premix is added after the conditioner or through a post-pellet liquid application system when extruded feed is produced at 85–95°C. Compliance is anchored to FDA 21 CFR Part 225.1–225.202 for medicated feed cGMP, EU Regulation 183/2005 on feed hygiene, EU Directive 2002/32/EC on undesirable substances in animal feed, and ISO 22000:2018 for feed safety management. Field observations in ribbon mixers show that dead zones at the end plates can retain 3–5 wt% of the batch; therefore, end-plate baffle clearance is checked every 20 batches and the mixer is run for an additional 2 min after any stoppage to reduce carryover. The terminal product classes are 0.1%, 0.5%, and 1% medicated premixes and feed additive concentrates, supplied in 20 kg or 25 kg multiwall bags.

At the tablet press, compression of Zhuling Powder–based tablets without a prior drying step is characterized by erratic weight variation, cap ejection, and punch filming because the API equilibrium moisture at 60% RH can exceed 9 wt%. A 500 mg tablet core contains 10–25 wt% Zhuling Powder, 50–70 wt% microcrystalline cellulose PH102, 3–5 wt% crospovidone as disintegrant, 1–2 wt% talc as anti-adherent, and 1–2 wt% sodium stearyl fumarate as lubricant. The moisture-sensitive fraction is dry granulated with a roller compactor using a 2 mm screen and 5–7 kN/cm roll force, producing granules with a bulk density of 0.48–0.60 g/mL. Compression is performed on a 12-station tablet press with 10 mm round concave tooling at 12–18 kN compression force, targeting hardness 60–100 N and disintegration below 15 min in water at 37°C. The tablet cores are film-coated with an aqueous ethylcellulose/hypromellose system at 2–3 wt% weight gain to reduce moisture ingress, then packed into 30 mL HDPE bottles. Compliance references are USP <701> disintegration, USP <1217> tablet breaking force, USP <711> dissolution, 21 CFR Part 210/211 for finished pharmaceutical manufacturing, and VICH GL3 for stability protocols. Production experience indicates that pre-drying at 45°C to Karl Fischer moisture below 5.0% is mandatory when the tableting suite RH exceeds 60%; otherwise, the powder adheres to the feed frame and weight variation exceeds the ±3% in-process control limit within 10 min of hopper residence.